UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual…
<!-- Name:DistributionId Value:8789512 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:HOWL
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of…
<!-- Name:DistributionId Value:8755898 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global…
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the…
Werewolf Therapeutics Added to the Nasdaq Biotechnology Index
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the…
Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally…
Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its…
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally…